Roche Holding stock gains as H1 sales rise 6 percent

Published on 10/05/2026 at 23:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock carries a CHF 30.36 billion first-half sales base, with group sales up 6 percent at constant exchange rates. The SIX quote reached CHF 347.40 on October 5, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding stock (ISIN CH1499059983) was trading at CHF 347.40 on SIX on October 5, 2026, up 0.5 percent during the session. The company entered the day with first-half 2026 group sales of CHF 30.36 billion, up 6 percent at constant exchange rates, according to Business News Today.

Half year sales set the base

Pharmaceutical sales reached CHF 23.63 billion in the first half, also growing 6 percent at constant exchange rates, according to Business News Today. The result gives Roche a substantial operating base as investors assess the pipeline against currency effects and upcoming product launches.

Roche's investor page reports core earnings per share of CHF 19.46 for fiscal year 2025, an increase of 11 percent at constant exchange rates. The same page identifies 2025 as the period in which 39 million patients received Roche medicines and 31 billion diagnostic tests were delivered.

Pipeline progress meets execution risk

At the September 28, 2026 Pharma Day, Roche described 10 positive Phase III readouts since the previous event and six new molecular entities advanced into Phase III, according to EarningsAPI. Management also raised its divarasib revenue expectation from USD 1 billion to USD 2 billion to USD 3 billion, tied to the strength of KRAScendo 1 data.

The counterweight is execution. Roche said a weak respiratory season reduced 2026 sales growth through Xofluza, while the transcript also described biosimilar pressure and currency effects. That combination makes late-stage launches and margin control central to the next leg of the investment case.

Analyst target stays above the quote

MarketScreener reported on September 8, 2026, that Barclays maintained a Buy rating and raised its Roche target from CHF 410 to CHF 430. A separate MarketScreener consensus page lists a Hold rating from 5 analysts and an average target of CHF 375.34, which is 8.0 percent above CHF 347.40.

For investors, the figures create a clear split: operating momentum is visible in the 6 percent first-half sales growth and 10 percent core profit growth, while the market is still weighing pipeline delivery, currency pressure and the timing of future launches.

Roche stock gains on October 5

Roche stock was trading at CHF 347.40 on SIX on October 5, 2026, with a 0.5 percent session gain. Roche's next scheduled investor event is its third-quarter sales presentation on October 22, 2026, at 2:00 p.m. CEST, according to Roche.